A Phase 2a, Proof of Concept, Open-label Study Evaluating the Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 07 Nov 2017
At a glance
- Drugs Etrasimod (Primary)
- Indications Inflammatory bowel diseases
- Focus Proof of concept; Therapeutic Use
- Sponsors Arena Pharmaceuticals
- 07 Nov 2017 According to an Arena Pharmaceuticals media release, status changed from recruiting to active, no longer recruiting.
- 24 Oct 2017 The trial has been discontinued in Germany.
- 20 Oct 2017 Trial has been completed in Belgium (end date: 2017-10-02)